Aerie Pharmaceuticals Overview

  • Founded
  • 2005
Founded
  • Status
  • Public
  • Employees
  • 365
Employees
  • Stock Symbol
  • AERI
Stock Symbol
  • Investments
  • 3
  • Share Price
  • $17.41
  • (As of Friday Closing)

Aerie Pharmaceuticals General Information

Description

Aerie Pharmaceuticals Inc is a clinical-stage pharmaceutical company. It is focused on the discovery, development, and commercialization of therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases, and retinal diseases. Its main products are Rhopressa and Roclatan. The company mainly operates in North America.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Pharmaceuticals
Other Industries
Biotechnology
Stock Exchange
NAS
Primary Office
  • 4301 Emperor Boulevard
  • Suite 400
  • Durham, NC 27703
  • United States
+1 (919) 000-0000

Aerie Pharmaceuticals Timeline

2018201920202021
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Aerie Pharmaceuticals Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$17.41 $17.87 $9.01 - $21.30 $816M 46.9M 562K -$3.82

Aerie Pharmaceuticals Financials Summary

In Thousands,
USD
TTM 31-Mar-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018
EV 823,547 634,786 980,403 1,404,922
Revenue 85,767 83,138 69,888 24,181
EBITDA (109,675) (119,206) (169,272) (228,478)
Net Income (175,936) (183,101) (199,581) (232,569)
Total Assets 362,728 402,045 452,608 285,044
Total Debt 230,054 225,502 206,255 0
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Aerie Pharmaceuticals Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Aerie Pharmaceuticals‘s full profile, request access.

Request a free trial

Aerie Pharmaceuticals Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Aerie Pharmaceuticals‘s full profile, request access.

Request a free trial

Aerie Pharmaceuticals Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Aerie Pharmaceuticals Inc is a clinical-stage pharmaceutical company. It is focused on the discovery, development, and c
Pharmaceuticals
Durham, NC
365 As of 2020
00000
000000 - 000 00000

00000000

enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo conseq
0000000000000
Lexington, MA
00 As of 0000
00000
00000000000 00000

00000000

aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. E
0000 000000000
Watertown, MA
000 As of 0000
00000
000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Aerie Pharmaceuticals Competitors (24)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Pulmatrix Formerly VC-backed Lexington, MA 00 00000 00000000000 00000
00000000 000000000 Corporation Watertown, MA 000 00000 000000000 00000
0000000 000000 Formerly VC-backed Redwood City, CA 00 00000 00000000 00000
00000000 Corporation Austin, TX 00 0000 00000000 0000
000000000 Formerly VC-backed South San Francisco, CA 00000 000.00 00000000000
You’re viewing 5 of 24 competitors. Get the full list »

Aerie Pharmaceuticals Executive Team (19)

Name Title Board Seat Contact Info
Vicente Anido Jr. Chief Executive Officer & Chairman of the Board
Thomas Mitro Chief Operating Officer, Operations & President
Richard Rubino Chief Financial Officer, Finance & Chief Accounting Officer, Accounting
Charlene Davis ESQ Chief Compliance Officer & Vice President
Casey Kopczynski Ph.D Chief Scientific Officer
You’re viewing 5 of 19 executive team members. Get the full list »

Aerie Pharmaceuticals Board Members (18)

Name Representing Role Since
Benjamin McGraw III Self Board Member 000 0000
David Gryska Self Board Member 000 0000
Geoffrey Duyk Ph.D Self Board Member 000 0000
Gerald Cagle Ph.D Self Board Member 000 0000
Julie McHugh Self Board Member 000 0000
You’re viewing 5 of 18 board members. Get the full list »

Aerie Pharmaceuticals Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Aerie Pharmaceuticals Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Aerie Pharmaceuticals‘s full profile, request access.

Request a free trial

Aerie Pharmaceuticals Investments & Acquisitions (3)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
000 000000 13-Dec-2019 000000000000000000 000.00 Biotechnology 0000000 00000 00.
0000000 0000000000 05-Oct-2017 000000000 00000 00 0000 Buildings and Property 0000000 00000 00.
Envisia Therapeutics (intellectual property rights ENV1105) 05-Oct-2017 Corporate Asset Purchase 0000 Buildings and Property
To view Aerie Pharmaceuticals’s complete investments and acquisitions history, request access »